Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Off-Label Coverage of Mycophenolate for Scleroderma under Medicare Part D

From the College  |  January 6, 2020

Based on a request by the ACR Insurance Subcommittee, off-label use of mycophenolate for scleroderma has been added to a Medicare-approved compendium.

Filed under:InsurancePractice SupportSystemic Sclerosis Tagged with:ACR Insurance Subcommittee (ISC)Medicare Part DMycophenolateoff-label useScleroderma

Phase 3 Results for Ixekizumab Promising in Patients with Non-Radiographic Axial Spondyloarthritis

Michele B. Kaufman, PharmD, BCGP  |  January 6, 2020

In a phase 3 study, ixekizumab proved safe and effective for improving the signs and symptoms of non-radiographic axial spondyloarthritis (axSpA) in combination with conventional background medications, such as NSAIDs…

Filed under:Drug Updates Tagged with:2019 ACR/ARP Annual Meetingaxial spondyloarthritis (SpA)ixekizumabnon-radiographic axial spondyloarthritis

The Educator’s Toolbox: How Clinicians Can Master the Art of Teaching & Giving Effective Feedback

Jason Liebowitz, MD, FACR  |  January 6, 2020

Insights into how to effectively teach & communicate feedback to students were offered in this Annual Meeting session…

Filed under:Education & TrainingProfessional Topics Tagged with:2019 ACR/ARP Annual MeetingEducationfeedbackteaching

EU Approves Remsima SC, a Biosimilar to Infliximab

Michele B. Kaufman, PharmD, BCGP  |  January 2, 2020

Subcutaneous CT-P13 (Remsima SC), biosimilar to infliximab, will soon be available in the E.U. to treat adults with rheumatoid arthritis…

Filed under:Biologics/DMARDsDrug Updates

Immunoassay May Help Identify Pediatric Lyme Arthritis

Marilynn Larkin  |  December 18, 2019

NEW YORK (Reuters Health)—In Lyme disease-endemic areas, a C6 peptide enzyme immunoassay (EIA) test may help guide initial management of children with acute arthritis, an observational study suggests.1 “Children with Lyme disease frequently present to the emergency department with an inflamed joint,” Lise Nigrovic, MD, MPH, of Boston Children’s Hospital tells Reuters Health by email….

Filed under:Conditions Tagged with:assayC6 peptide enzyme immunoassay (EIA)Lyme arthritisLyme Disease

Declining Numbers of Americans Have a Primary Care Provider

Natasha Yetman  |  December 18, 2019

(Reuters Health)—In a little over a decade, the number of patients in the U.S. with primary care providers dropped by 2%, a new study finds. Between 2002 and 2015, fewer and fewer Americans of all ages, except for those in their 80s, had a primary care provider, researchers report in JAMA Internal Medicine.1 Although 2%…

Filed under:Professional Topics Tagged with:primary carePrimary Care Physician

Rheum After 5: Dr. Stacy Ardoin & Mr. Mom

Carol Patton  |  December 18, 2019

In 2004, Stacy Ardoin, MD, MHS, became pregnant with twins during the second year of her fellowship at Duke University School of Medicine, Durham, N.C. Although she and her husband, Adrien, were thrilled by the news, the astronomical cost of day care for two infants was a specter. At the time, Adrien managed a book­store…

Filed under:Rheum After 5 Tagged with:Dr. Stacy Ardoin

Fall 2019’s Awards, Appointments & Announcements in Rheumatology

Gretchen Henkel  |  December 18, 2019

J. Michelle Kahlenberg Receives Presidential Early Career Award for Scientists & Engineers (PECASE) A physician scientist and associate professor of internal medicine in the Division of Rheumatology at the University of Michigan in Ann Arbor, J. Michelle Kahlenberg, MD, PhD, is a 2019 recipient of the prestigious PECASE award. Dr. Kahlenberg, who also holds the…

Filed under:AwardsProfiles Tagged with:Dr. J. Michelle KahlenbergErica CrosleyErica MooreKathryn WierengaLin ChenPhilip CarlucciThomas Winans

Ankylosing Spondylitis & Uveitis: An Ophthalmologist’s Perspective

Jason Liebowitz, MD, FACR  |  December 18, 2019

It’s often said the eyes are the window to the soul, and in the case of ankylosing spondylitis and other spondylo­arthropathies, one can also say the eyes are the window to systemic disease. Although uveitis occurs in approximately 2–5% of patients with inflammatory bowel disease, 6–9% of patients with psoriatic arthritis and 25% of patients…

Filed under:Axial SpondyloarthritisConditions Tagged with:Ankylosing SpondylitisAS Resource CenterHLA-B27opthamologistUveitis

Lessons from Master Clinicians: An Interview with Dr. Paul Plotz

Jason Liebowitz, MD, FACR  |  December 18, 2019

Rheumatologists who are outstanding clinicians, provide consistently exceptional care to patients and serve as role models for colleagues and trainees are in the spotlight in our Lessons from a Master Clinician series. Here, we offer insights from clinicians who have achieved a level of distinction in the field of rheumatology. Paul Plotz, MD, is scientist…

Filed under:Patient PerspectiveProfessional TopicsProfiles Tagged with:Dr. Paul PlotzLessons from Master CliniciansRole Models in Rheumatology

  • « Previous Page
  • 1
  • …
  • 109
  • 110
  • 111
  • 112
  • 113
  • …
  • 324
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences